Drug Trial Radar · NCT00790218
A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: May 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Feb 2009
Primary completion
Dec 2012
Study completion Dec 2013
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis. Treatment will be assessed for adverse effects and for effects on the tumor.
Conditions
- Hepatocellular Carcinoma
Interventions
CF102Drug
CF102 capsules twice daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting ToxicityTime frame: From start of treatment until Day 28 of Cycle 1
- Maximum Tolerated DoseTime frame: first 28 days (Cycle 1)
- Maximum Plasma Concentration of CF102 (Cmax)Time frame: Dose Escalation Phase on Day 1 and Day 29 pre-dose and at 1, 2, 3, 4, 6, 8 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rabin Medical Center
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.